BNP Paribas Asset Management
XLRN

BNP Paribas Asset Management’s Acceleron Pharma XLRN Stock Holding History

BNP Paribas Asset Management’s Portfolio XLRN Stock Details XLRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-107,808
Closed -$18.6M – 960
2021
Q3 		$18.6M Sell
107,808
-75,566
-41% -$9.88M 0.07% 310
2021
Q2 		$23M Buy
183,374
+33,634
+22% +$4.24M 0.08% 282
2021
Q1 		$20.3M Sell
149,740
-45,157
-23% -$5.83M 0.08% 281
2020
Q4 		$24.9M Buy
194,897
+81,205
+71% +$9.52M 0.12% 214
2020
Q3 		$12.8M Buy
113,692
+34,936
+44% +$3.48M 0.07% 285
2020
Q2 		$7.5M Buy
78,756
+60,352
+328% +$5.82M 0.05% 354
2020
Q1 		$1.65M Sell
18,404
-2,654
-13% -$206K 0.01% 558
2019
Q4 		$1.12M Buy
+21,058
New +$960K 0.01% 646

BNP Paribas Asset Management's XLRN Position: Q4 2021 in Review

BNP Paribas Asset Management sold out of Acceleron Pharma (XLRN) in Q4 2021, closing a stake of 107,808 shares — an estimated $18.6M sold.

BNP Paribas Asset Management first reported a position in XLRN in Q4 2019 and held it in 8 quarters. The position peaked at $24.9M in Q4 2020. 1 fund tracked by Wall St. Rank holds XLRN as of Q4 2021.

  • BNP Paribas Asset Management reported no remaining Acceleron Pharma position as of Q4 2021 after selling out during the quarter.
  • BNP Paribas Asset Management sold 107,808 Acceleron Pharma shares in Q4 2021, an estimated $18.6M.
  • BNP Paribas Asset Management first reported a position in Acceleron Pharma in Q4 2019 and held it in 8 quarters.
  • BNP Paribas Asset Management's Acceleron Pharma position peaked at $24.9M in Q4 2020.
  • 1 fund tracked by Wall St. Rank held Acceleron Pharma as of Q4 2021.

Based on BNP Paribas Asset Management's 13F filing for Q4 2021, filed 9 Feb 2022.